Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Abortion battle shifts to US Congress and midterm elections
    • Abortion ruling shows growing might of US Supreme Court’s conservatives
    • ‘We’re going backwards’: a divided America reacts to abortion decision
    • Xi Jinping to make first trip outside mainland China for Hong Kong ceremony
    • US Supreme Court overturns Roe vs Wade in major blow to abortion rights
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Abortion battle shifts to US Congress and midterm elections
    • A devastating blow to women’s rights in America
    • The case against Trump: Has the January 6 committee changed minds?
    • Abortion ruling shows growing might of US Supreme Court’s conservatives
    • ‘We’re going backwards’: a divided America reacts to abortion decision
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Rising rates raise prospect of property crash
    • BioNTech/Pfizer say Omicron-targeting boosters elicit strong immune response
    • UK ‘altnets’ risk digging themselves into a hole
    • Pornhub owner MindGeek loses top two executives
    • Michael Saylor: MicroStrategy’s bitcoin true believer
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Stocks snap weekly losing streak on scaled back rate-rise expectations
    • Investors are on recession watch
    • History says US stock market has further to fall
    • Is it too early for investors to buy the dip?
    • Meet Zoltan, the sellside Jules Verne
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • A devastating blow to women’s rights in America
    • Who is worse company, the left or the right?
    • Far from the battlefield, Moscow’s generals fight a falling birth rate
    • Rethinking the way we travel
    • Your phone’s notification settings and the meaning of life
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Why pay rises for your company’s ‘flight risks’ can backfire
    • Humour in the office matters, but can a boss be funny?
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Inside the secret, often bizarre world that decides what porn you see
    • Who is worse company, the left or the right?
    • Writer Vladimir Sorokin: ‘I underestimated the power of Putin’s madness’
    • Abortion in America — the road to rolling back Roe vs Wade
    • Best summer books of 2022: Critics’ picks
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Merck & Co Inc

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Wednesday, 16 February, 2022
    Coronavirus treatment
    Merck struggles to win European approval for Covid antiviral pill

    EMA said to be unlikely to grant marketing authorisation to molnupiravir this month after ‘problematic’ data

  • Wednesday, 22 December, 2021
    Covid-19 vaccines
    France cancels order for Merck antiviral tablet on efficacy fears

    Concerns grow over molnupiravir’s ability to reduce Covid hospitalisations and deaths

  • Sunday, 5 December, 2021
    Coronavirus treatment
    Merck takes aim at Pfizer’s Covid pill as concerns linger over its own drug

    Executive says patients on other medications will not be able to take competing antiviral treatment

  • Tuesday, 30 November, 2021
    Coronavirus treatment
    Merck’s Covid pill secures narrow backing from US regulatory panel

    Experts advising FDA recommend treatment for high-risk patients amid fears over Omicron variant

  • Friday, 26 November, 2021
    Coronavirus treatment
    Merck says its Covid antiviral treatment less effective than first thought

    Full analysis of trial results shows molnupiravir had a risk reduction of 30%

  • Friday, 12 November, 2021
    The Big Read
    The Covid drugs are finally here

    New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?

  • Thursday, 4 November, 2021
    Coronavirus treatment
    Merck’s Covid pill Lagevrio secures green light from UK regulator

    First authorisation for antiviral drug that halves risk of hospitalisation or death

  • Wednesday, 27 October, 2021
    Coronavirus treatment
    Merck signs royalty-free deal to expand access to its Covid-19 pill

    Move contrasts with mRNA makers Pfizer and Moderna, which have rejected sharing vaccine technology

  • Tuesday, 12 October, 2021
    LexCoronavirus treatment
    Coronavirus pill: Merck forges a new hammer to crack pandemic Premium content

    Molnupiravir has limitations but drugmakers should be able to build on it to create other treatments

  • Tuesday, 12 October, 2021
    Coronavirus treatment
    Merck aims to double supply of Covid-19 antiviral pill on rising demand

    Drugmaker seeks authorisation from FDA for oral treatment shown to prevent severe disease in vulnerable people

  • Wednesday, 6 October, 2021
    News in-depthPharmaceuticals sector
    Merck on deals hunt as patent cliff looms for top cancer drug

    Investors fret over how company will fare when Keytruda loses exclusivity

  • Friday, 1 October, 2021
    Coronavirus treatment
    Merck says Covid antiviral pill halves risk of hospitalisation and death

    US pharma group seeks authorisation for first drug of its kind after ‘remarkable’ clinical trial

  • Thursday, 30 September, 2021
    Merck to buy Acceleron Pharma for $11.5bn

    Acquisition will expand US pharmaceutical company’s pipeline of cardiovascular treatments

  • Thursday, 3 June, 2021
    Medical science
    AstraZeneca and Merck point to progress in fighting breast cancer

    Lynparza shown to reduce recurrence rates, while Novartis to unveil new type of radiotherapy

  • Wednesday, 10 March, 2021
    News in-depthFT Film24 min
    Covid-19 and the business of vaccines

    New vaccine producers and mRNA technology are shaking up the market

  • Tuesday, 2 March, 2021
    Covid-19 vaccines
    Biden says US will have enough jabs to vaccinate all adults by end of May

    White House announces accelerated timeline after brokering production deal between J&J and Merck

  • Friday, 26 February, 2021
    UK business & economy
    Cancer drug is first to begin fast-track UK approval process

    Approach seeks to cut years off traditional licensing process for treatments

  • Tuesday, 16 February, 2021
    News in-depthCovid-19 vaccines
    Why the three biggest vaccine makers failed on Covid-19

    GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology

  • Thursday, 4 February, 2021
    Merck chief Kenneth Frazier to retire this summer

    Executive vice-president Robert Davis will take helm at US drugmaker

  • Monday, 25 January, 2021
    Covid-19 vaccines
    Merck abandons bid to develop Covid-19 vaccine

    After lacklustre results, company says it will shift focus to potential drugs to treat the disease

  • Tuesday, 18 August, 2020
    Merck plans to build £1bn UK research hub in central London

    US pharma group says Britain is ‘world leader’ in developing science

  • Tuesday, 30 June, 2020
    Coronavirus treatment
    The hedge fund manager behind a long-shot coronavirus pill

    Wayne Holman and his wife Wendy are betting they can change the course of the pandemic

  • Friday, 5 June, 2020
    News in-depthKenneth Frazier
    Kenneth Frazier, the Merck boss taking a stand against racial injustice

    Pharma group’s publicity-shy chief has made a remarkable intervention over George Floyd’s killing

  • Wednesday, 27 May, 2020
    Drugs research
    Merck adopts ‘error catastrophe’ coronavirus drug

    Pill that aims to force virus to mutate to self-destruction set for extensive clinical trials in US and UK

  • Tuesday, 26 May, 2020
    InterviewCoronavirus pandemic
    Merck chief casts doubt on coronavirus vaccine timeframe

    Ken Frazier calls 12 to 18-month targets ‘very aggressive’ as he announces biotech acquisition

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In